Mr. Bill Mitoulas reports

MEDX ANNOUNCES PROPOSED NON-BROKERED PRIVATE PLACEMENT TO RAISE UP TO $1,500,000 AND INTENTION TO SEEK ACCEPTANCE FOR AMENDMENT TO WARRANTS

MedX Health Corp. is proposing to raise up to $1.5-million by way of a non-brokered private placement of up to 21,428,571 units at seven cents per unit. Each unit will comprise one fully paid common share and one share purchase warrant, exercisable to purchase one further common share at the price of 12 cents, exercisable for a period commencing on the date of issue and expiring on Dec. 31, 2026. Closing of the placement, which may take place in tranches, will be subject to receipt of subscriptions for a minimum of $500,000 and a number of other conditions, including, without limitation, the receipt of all relevant regulatory and stock exchange approvals or acceptances. Qualified agents may receive commissions in respect of subscriptions introduced by them by way of cash equal to 6 per cent of funds so introduced, and issuance of agent warrants equal in number to 6 per cent of the number of units so subscribed for. Each agent warrant, which is non-transferable, will be exercisable to acquire one unit at seven cents per unit, at any time during the period of two years following the closing.

Further to its press release dated June 16, 2023, MedX Health Corp. is making an application to the TSX Venture Exchange for acceptance of the proposed amendment to the terms of 17,495,472 share purchase warrants issued in April, May and July, 2020, in connection with private placements completed at that time. Pursuant to acceptance by the TSX-V during 2022, the expiration date of the 2020 warrants was extended to Dec. 31, 2023. Subject to and conditional on acceptance by the TSX-V, the company will amend the exercise price of the 2020 warrants from 20 cents to 14 cents and will further extend the expiration date of the 2020 warrants to June 30, 2024. Each of the 2020 warrants is exercisable to purchase one common share from the treasury of MedX.

About MedX Health Corp.

MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy on DermSecure telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also embedded in its products Siametrics, Simsys and MoleMate, which MedX manufactures in its ISO 13485 certified facility. Siametrics, Simsys and MoleMate include hand-held devices that use patented technology utilizing light and its remittance to view up to two millimetres beneath suspicious moles and lesions in a pain-free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration, and Conformite Europeenne for use in Canada, the United States, Australia, New Zealand, the European Union, Brazil and Turkey.

We seek Safe Harbor.